Haemolytic Uraemic Syndrome
(asked on 19th January 2024) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the paper in Epidemiology and Infection 2023; 151: e160, entitled Haemolytic uraemic syndrome in children England, Wales, Northern Ireland, and Ireland: A prospective cohort study, published on 1 September 2023, if she will take steps to publish more accurate data on the number of cases of Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome identified by the UK Health Security Agency; and if her Department will take steps to increase funding for research into (a) cures and (b) treatments to improve long-term health outcomes for this illness.
Answered by
Maria Caulfield
Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Haemolytic Uraemic Syndrome (HUS) is a notifiable disease and cases are reported on a weekly basis by the UK Health Security Agency (UKHSA). The most common type of Shiga toxin-producing E.coli associated with HUS is also a notifiable pathogen, and the number of laboratory reported cases is published on a weekly basis by UKHSA. This data covers England and Wales, and is available at the following link:
The Department commissions research through the National Institute for Health and Care Research (NIHR). As the largest public funder for health and care research, the NIHR welcomes funding applications for research into any aspect of human health, including cures and treatments for HUS.